Insider Buy ·Filed Jun 3, 2026

AUPH

Aurinia Pharmaceuticals Inc.
BULLISH
Impact 6/10
Horizonweeks Processed3mo ago SECAUPH-1780949450182
Insider cluster: 1 insiders, $8.4M total
Actionable Insight ▲ Bullish

CEO Tang's concentrated $8.4M buy near multi-week lows (mid-$15s) is a strong, standalone conviction signal. Monitor for a concurrent or upcoming corporate catalyst (e.g., pipeline milestone, NDA filing, or strategic update) that could explain the timing. If stock trades below Tang's average entry price (~$15.28) without new adverse news, the insider purchase pattern suggests accumulation opportunity for long-side traders.

DirectionBullish
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
AUPH ▲ +5.14% at T+60d
LONG call ✓ call won +5.14% · α vs SPY +2.90% · entry $15.67 → $16.48
Entry anchored
Jun 2, 03:59 PM ET
via exchange tick
T+1d
+4.47%
call +4.47% · α +4.09%
$16.37
settled 4mo ago
T+5d
-0.06%
call -0.06% · α +3.76%
$15.66
settled 4mo ago
T+20d
+0.83%
call +0.83% · α +1.95%
$15.80
settled 3mo ago
T+60d
+5.14%
call +5.14% · α +2.90%
$16.48
settled 5w ago

Price Chart

Loading chart...

Executive Summary

Aurinia CEO Kevin Tang made a conviction buy of ~552K shares (~$8.4M in open-market purchases) over three days, with bulk of buying at $15.28 on June 1-2. This represents ~0.4% of the $2.1B market cap — a material, proportionally meaningful insider buy from the company's top executive. The purchase is inconsistent with diversification or 10b5-1 pattern and signals the CEO's view that the stock is undervalued at current levels.

Key Financial Metrics

Direction
buying
Total Value
$8.4M
Insiders
1

Key Facts

  • CEO Kevin Tang purchased ~552K shares for ~$8.4M over May 29–June 2, 2026
  • Largest single-day purchase was 343.5K shares at $15.28 on June 1 (~$5.3M)
  • Purchases represent ~0.4% of the company's $2.1B market cap
  • CEO acts as the sole insider buyer — no other insider sold or bought during the window
  • No identified 10b5-1 pattern; purchases clustered over consecutive trading days at near-identical prices

Financial Impact

$8.4M in open-market CEO stock purchases (~0.4% of market cap)

insider ownershipfloat

Risk Factors

  • Biotech sector risk; single-asset / single-pipeline reliance may drive stock price independent of insider views
  • Insider buys material by dollar value but represent <0.5% of market cap — not transformative on its own
  • No additional C-suite or board buys to confirm shared conviction; lone-CEO buy could be personal conviction not shared by wider management
  • Historical calibration shows segment score-6 filings have only 34% observed win rate at T+20, though mean win alpha is +14.9% versus mean loss alpha of -15.6%

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
69% bullish (13 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
INSIDER-BUY Data (Synthetic)AUPH-1780949450182
4 reports for AUPH
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for AUPH — sortable, filterable
TypeNow
Aug 6, 2026
8w ago
8-K
BULLISH ★ 6/10
$16.13 $16.12▼ −0.06%▼ −0.66%$15.85 (−1.74%)
Jun 3, 2026
17w ago
Insider Buy
BULLISH ★ 6/10
$15.67 $15.80▲ +0.83%▲ +1.95%$15.85 (+1.15%)
May 11, 2026
20w ago
8-K
NEUTRAL ★ 5/10
$15.72 $15.78▲ +0.38%▲ +0.69%$15.85 (+0.83%)
Feb 26, 2026
31w ago
8-K
BULLISH ★ 8/10
$13.97 $14.60▲ +4.51%▲ +10.91%$15.85 (+13.46%)
Showing 4 of 4

US Market Status

Market Open — Closes in 2h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access